Please assess the completion status of the following clinical trial:

Trial Title: EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Able and willing to give written informed consent~2. Age ≥55 years~3. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye (except if the subject is monocular)~4. Have GA lesion(s) total size between or equal to 1.25mm2 to 17.5mm2 in the study eye~5. The GA lesion(s) in the study eye must reside completely within the FAF image~6. Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye, defined as either:~   1. Non-exudative/sub-clinical fellow eye CNV identified at Screening, or~  2. Known history of fellow eye CNV with either ≥2 years since diagnosis or with no active treatment required in 6 months prior to Screening~7. Have a BCVA of 24 letters (6/95 and 20/320 Snellen acuity equivalent) or better, using ETDRS charts, in the study eye~8. Part 1 Only: Subjects carrying a CFI rare variant genotype (minor allele frequency of ≤1%) previously associated with low serum CFI or subjects carrying an unreported CFI rare variant genotype that have tested to have a low serum CFI~9. Able to attend all study visits and complete the study procedures~10. Women of child-bearing potential must have a negative pregnancy test within 2 weeks prior to randomisation. A pregnancy test is not required for postmenopausal women (defined as being at least 12 consecutive months without menses) or those surgically sterilised (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy)~Exclusion Criteria:~1. Subjects who have a clinical diagnosis of Stargardt Disease or other retinal dystrophies, confirmed by the central reading centre~2. Have a history, or evidence, of CNV in the study eye~3. Presence of moderate/severe or worse non-proliferative diabetic retinopathy in the study eye~4. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye~5. History of intraocular surgery in the study eye within 12 weeks prior to Screening (Visit 1). Yttrium aluminium garnet capsulotomy is permitted if performed \>10 weeks prior to Visit 1~6. Have clinically significant cataract that may require surgery during the study period in the study eye~7. Presence of moderate to severe glaucomatous optic neuropathy in the study eye; uncontrolled IOP despite the use of two or more topical agents; a history of glaucoma-filtering or valve surgery is also excluded~8. Axial myopia of greater than -8 dioptres in the study eye~9. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study~10. Have a contraindication to specified protocol corticosteroid regimen~11. Have received any investigational and/or approved product(s) for the treatment of GA within the past 6 months, or 5 half-lives (whichever is longer) other than nutritional supplements such as the age-related eye disease study (AREDS) formula in the study eye or systemically~12. Have received a gene or cell therapy at any time~13. Are unwilling to use two forms of contraception (one of which being a barrier method) for 90 days post-dosing, if relevant~14. Active malignancy within the past 12 months, except for: appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) ≥12 months

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 - GT005 Low Dose (Type: EXPERIMENTAL): Approximately 25 subjects are planned, with subjects randomised to GT005 Low Dose.
- Part 1 - GT005 High Dose (Type: EXPERIMENTAL): Approximately 25 subjects are planned, with subjects randomised to GT005 High Dose.
- Part 1 - Untreated control (Type: NO_INTERVENTION): Approximately 25 subjects are planned, with subjects randomised to untreated control.
- Part 2 - GT005 Low Dose (Type: EXPERIMENTAL): Approximately 116 subjects are planned, with subjects randomised to Part 2 - GT005 Low Dose.
- Part 2 - Untreated control (Type: NO_INTERVENTION): Approximately 54 subjects are planned, with subjects randomised to untreated control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy